DowDuPont has announced actions to achieve a $3-billion cost synergy target as part of its post-merger integration plans. The company made the announcement as part of its third-quarter earnings results, its first earnings report as a combined company. Read More

The FDA has updated its efforts in supporting pharmaceutical manufacturing in Puerto Rico following Hurricanes Irma and Maria. The FDA is monitoring approximately 90 products (50 medical devices, 30 drug products, and 10 biological devices/biologics) to help mitigate potential shortages. Read More

Amgen plans to reduce its research and development (R&D) staff by approximately 200 positions by the end of 2017 across R&D sites as part of organizational changes. Read More

Roche plans to cut 130 workers at its biomanufacturing site in Vacaville, California by the end of 2017 and cut an additional 235 positions at its site in Kaiseraugst, Switzerland, which currently hosts quality control and packaging for small-molecule drugs as well as IT. Read More

DowDuPont has closed a business swap with FMC Corporation under which FMC acquired a portion of the former DuPont crop protection business and DowDuPont acquired FMC’s health and nutrition business, which includes its excipient business. Read More

FDA Commissioner Scott Gottlieb has outlined the agency’s approach to increasing generic-drug competition by prioritizing generic-drug reviews and addressing potential misuse of the Risk Evaluation and Mitigation Strategy (REMS) system. Read More

Valeant is selling back its subsidiary, Sprout Pharmaceuticals, to Sprout’s former shareholders for a 6% royalty on sales of Sprout’s lead product, a women’s health drug. Valeant acquired Sprout for $1 billion in 2015. The sale is expected to close before the end of 2017. Read More

Teva has completed a $675-million sale of its emergency contraceptive, Plan B One-Step, and its value brands of emergency contraception products to Foundation Consumer Healthcare, a Pittsburgh, Pennsylvania-headquartered pharmaceutical products developer. Read More

Amgen and Kirin Holdings have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture for $780 million and, as a result, Kirin-Amgen will become a subsidiary of Amgen.   Read More

The European Medicines Agency, based in London, has updated the agency’s progress with its relocation to a new host city in the wake of the UK’s decision to exit the European Union. Read More